SLV 308 in People with Advanced Parkinson’s Disease Experiencing Motor Disturbances
Official Study Title: The Mondrian Study: A multicenter, randomized, double-blind, placebo-controlled, parallel group study of SLV 308 as adjunct therapy to levodopa in patients with Parkinson’s disease experiencing motor fluctuations
Sponsor: Solvay Pharmaceuticals, Inc.
Clinicaltrials.gov ID : NCT00406588
Study ID : SLV 308.3.002
Last Updated Date: 25 Jun 2007
- General PD symptoms
- Loss of Motor Skills
This is a study of 12 weeks treatment with SLV 308 as an adjunctive treatment (treatment in addition to levodopa) for participants with advanced Parkinson’s disease (PD). The study is planned for 85 centers in 13 countries and is intended to enroll 280 participants globally, 90 of which will be in the U.S. An extension to this study is planned as a separate trial for those participants who are willing and eligible to participate.
READ MORE at PDTrials.org